Payment overview · 2025
General Payments
$100.22
5 reported records · 4 companies
Healthcare provider profile · identity verified
John C House, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NAHUNTA, GA · NPI 1346348133
Verified facts
What the public records show
CMS Open Payments records show John C House, M.D. received $100.22 in general payments during 2025 across 5 reported records.
Astellas Pharma US Inc accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.00 | 39.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.89 | 20.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.78 | 20.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.55 | 18.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.22 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 630 | 106 |
| Gabapentin | Gabapentin | 332 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 69 |
| Meloxicam | Meloxicam | 258 | 62 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 256 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 62 |
| Lisinopril | Lisinopril | 237 | 57 |
| Omeprazole | Omeprazole | 225 | 54 |
| Furosemide | Furosemide | 209 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 42 |
| Alprazolam | Alprazolam | 186 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 32 |
| Losartan Potassium | Losartan Potassium | 174 | 41 |
| Trazodone Hcl | Trazodone Hcl | 159 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 30 |
| Simvastatin | Simvastatin | 142 | 37 |
| Tramadol Hcl | Tramadol Hcl | 141 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 33 |
| Azithromycin | Azithromycin | 122 | 91 |
| Metformin Hcl | Metformin Hcl | 122 | 37 |
| Carvedilol | Carvedilol | 119 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 22 |
| Lorazepam | Lorazepam | 108 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 21 |
| Prednisone | Prednisone | 92 | 52 |
| Glimepiride | Glimepiride | 91 | 30 |
| Montelukast Sodium | Montelukast Sodium | 89 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 19 |
| Clonazepam | Clonazepam | 84 | 13 |
| Famotidine | Famotidine | 79 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 25 |
| Diazepam | Diazepam | 77 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 76 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 26 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 18 |
| Sertraline Hcl | Sertraline Hcl | 65 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | suppressed |
| Ibuprofen | Ibuprofen | 62 | 17 |
| Allopurinol | Allopurinol | 60 | 11 |
| Spironolactone | Spironolactone | 59 | 12 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Mupirocin | Mupirocin | 56 | 16 |
| Methadone Hcl | Methadone Hcl | 55 | suppressed |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 12 |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Temazepam | Temazepam | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Linzess | Linaclotide | 45 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Colchicine | Colchicine | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Cephalexin | Cephalexin | 29 | 17 |
| Amoxicillin | Amoxicillin | 28 | 20 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.22 · 5 records | Astellas Pharma US Inc | FANAPT, General - Pain Management, Ozempic, Rybelsus, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error